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Case Report
A Case of Stenotrophomonas maltophilia Keratitis 
Effectively Treated with Moxifloxacin
Sung Whan Son, Hyung Jin Kim, Jeong Won Seo
Department of Ophthalmology, Sahm Yook Medical Center, Seoul, Korea
A 70-year-old man with a long history of diabetes mellitus presented to our hospital (Department of Ophthalmology, 
Sahm Yook Medical Center, Seoul, Korea) complaining of severe ocular pain and visual disturbance in his left eye 
that had started three days prior to admission. A round 3.7 × 5.0 mm dense central stromal infiltrate with an over-
lying epithelial defect was noted on slit-lamp examination. Following corneal scrapings and culture, topical 0.5% 
moxifloxacin and 0.5% tobramycin were administered hourly. A few days later, Stenotrophomonas maltophilia was 
isolated in a bacterial culture from a corneal specimen. According to the results of susceptibility tests, topical 0.5% 
moxifloxacin was given every hour and 0.5% tobramycin was stopped. The patient's clinical features improved 
steadily with treatment. The corneal epithelium healed rapidly, and the infiltrate resolved within four weeks of the ini-
tiation of treatment. The patient’s best corrected visual acuity improved from hand motion to 20 / 25.
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Stenotrophomonas maltophilia (S. maltophilia) is a non- 
fermentative, gram-negative bacillus that has assumed an in-
creasingly important role as a nosocomial pathogen in im-
mune compromised patients [1]. Treatment of S. maltophilia 
infections is also complicated by the fact that isolates are re-
sistant to many broad-spectrum agents [2]. Ophthalmologic 
syndromes, including conjunctivitis, keratitis, dacrocystitis 
and pre-septal cellulitis, may be caused by S. maltophilia [3]. 
S. maltophilia keratitis is associated with very poor prog-
noses because of its resistance to many broad-spectrum anti-
biotics [4]. We describe a case of S. maltophilia keratitis that 
was effectively treated with topical moxifloxacin (fourth- 
generation fluoroquinolone) monotherapy.
Case Report
A 70-year-old male presented to our hospital (Department 
of Ophthalmology, Sahm Yook Medical Center, Seoul, 
Korea) with a three-day history of left eye pain and decreased 
vision. He had a long history of diabetes mellitus that was 
controlled with oral anti-hyperglycemic agents. The patient 
suffered from bilateral proliferative diabetic retinopathy and 
had undergone pan retinal photocoagulation several times 
since March 1995. At age 60 he had undergone phacoemulsi-
fications with intraocular lens implantation for the treatment 
of senile cataracts in both eyes. 
On presentation, the patient’s visual acuity was hand mo-
tion in the left eye. Slit lamp examination revealed a heavily 
edematous cornea and a round 3.7 × 5.0 mm dense central 
stromal infiltrate with an overlying epithelial defect (Fig. 1). 
Anterior chamber cells 3+ and ciliary injection were also 
observed.
After scrapings were collected from the lesion for smears 
and cultures, the patient was treated hourly with 0.5% moxi-
floxacin and 0.5% tobramycin. Four days after the initiation 
of treatment, heavy growth of S. maltophilia was observed in 
culture. The isolated bacteria were sensitive to ciprofloxacin, 
sulfamethoxazole-trimethoprim, levofloxacin, and moxi-
floxacin, but were resistant to all aminoglycosides and B-lac-
tams (Table 1). According to the results of susceptibility 
tests, topical 0.5% moxifloxacin was given every hour and 
0.5% tobramycin was stopped.
The patient’s corneal epithelium healed in two weeks after 
the initiation of treatment. After the epithelium had healed, 
moxifloxacin was administered four times per day. The cor-
neal infiltrate resolved within four weeks. However, mild 
opacity remained in the posterior stroma (Fig. 1). The pa-Korean J Ophthalmol Vol.25, No.5, 2011
350
A B
Fig. 1. (A) Photograph of the cornea shows an approximately 3.7 × 5.0 mm epithelial defect and infiltrated stromal lesion at the time of 
admission. (B) Photograph of the cornea shows healed epithelium with mild posterior stromal opacity after four weeks of treatment.
Table 1. Results of antimicrobial sensitivity tests
Antibiotic MIC
Amikacin R (<16)
Gentamicin R (>8)
Tobramycin R (>8)
Imipenem R (>8)
Cefazolin R (>16)
Cefuroxime sodium R (>16)
Ceftazidime R (>8)
Cefotaxime R (>32)
Ampicillin R (>16)
Piperacillin R (>64)
Sulfamethoxazole-Trimethoprim S (≤0.5)
Ciprofloxacin S (≤1)
Levofloxacin S (≤0.5)
Moxifloxacin S (≤0.5)
MIC = minimal inhibitory concentration; R = resistant; S = 
sensitive.
tient’s best corrected visual acuity improved from hand mo-
tion to 20 / 25. His infectious keratitis was controlled and had 
not recurred at the one-year follow-up examination.
Discussion
S. maltophilia is a motile, non-fermentative, oxidase-neg-
ative, aerobic, Gram-negative bacillus that is widespread in 
the environment [5]. It is an opportunistic pathogen believed 
to have limited pathogenicity unless it is associated with no-
socomial infections of immune compromised patients [6]. S. 
maltophilia is a seldom-reported pathogen in lens care systems 
or ocular infections [7]. However, reports of postoperative 
and post-traumatic S. maltophilia ocular infections are increas-
ing [8]. The reasons underlying this emergence are complex, 
but may be related to the improved laboratory isolation tech-
niques and enhanced reporting. Treatment of S. maltophilia 
infections is complicated by the fact that isolates are often re-
sistant to many broad-spectrum antibiotic agents [2].
You et al. [4] reported the treatment results and prognoses 
of 10 cases of S. maltophilia keratitis in 2007 after one time 
applications of levofloxacin ophthalmic solution as a first 
line treatment of choice before culture results. They then 
added fortified tobramycin and cefazolin if corneal ulcers 
were large and centrally located of the cornea. Patients also 
underwent surgical treatment when there was no response to 
medication. The final visual acuity in three cases that had no 
co-infections was worse than hand motion. 
Fourth-generation fluoroquinolones (moxifloxacin and 
gatifloxacin) show an enhanced spectrum of activity against 
Gram-positive bacteria and comparable activity to second- 
and third-generation fluoroquinolones (ciprofloxacin and 
levofloxacin) against Gram-negative bacteria [9]. New ocu-
lar antibiotic formulations with improved potency, such as 
moxifloxacin ophthalmic solution 0.5% (Vigamox
®; Alcon 
Laboratories, Fort Worth, TX, USA) or gatifloxacin oph-
thalmic solution 0.3% (Zymar
®; Allergan, Irvine, CA, USA) 
are currently available and have been shown to inhibit 
growth of organisms resistant to second- and third-gen-
eration fluoroquinolones [10]. Several in vitro susceptibility 
studies, demonstrate that moxifloxacin is more active than 
earlier generation fluoroquinolones (ciprofloxacin, oflox-
acin, and levofloxacin), especially against S. maltophilia [9]. 
For these reasons, we chose moxifloxacin monotherapy for 
treatment of S. maltophilia keratitis, even though antibiotic 
sensitivity was equal for both levofloxacin and moxifloxacin.
In conclusion, we report the case of a patient who was di-
agnosed with S. maltophilia keratitis and effectively treated 
with moxifloxacin monotherapy. Unlike most previously-re-
ported cases, which had poor prognoses, in our patient moxi-
floxacin monotherapy led to a good visual outcome.
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